Jakob R Passweg

List of Publications by Year
in descending order

117 papers	5,293 citations	361413 20 h-index	85541 71 g-index
123 all docs	123 docs citations	123 times ranked	6940 citing authors

#	Article	IF	Citations
1	Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin. Bone Marrow Transplantation, 2022, 57, 391-398.	2.4	5
2	Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia. Current Oncology, 2022, 29, 805-815.	2.2	3
3	Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study. Bone Marrow Transplantation, 2022, 57, 613-619.	2.4	7
4	Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplantation, 2022, 57, 742-752.	2.4	45
5	Antibody response to mRNA SARSâ€CoVâ€2 vaccination in 182 patients after allogeneic hematopoietic cell transplantation. Transplant Infectious Disease, 2022, , .	1.7	10
6	Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2022, 57, 903-910.	2.4	11
7	External Validation of the Revised Pretransplant Assessment of Mortality Score in Allogeneic Hematopoietic Cell Transplantation: A Cohort Study. HemaSphere, 2022, 6, e704.	2.7	2
8	Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma. Cytotherapy, 2021, 23, 329-338.	0.7	12
9	Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial. Annals of Hematology, 2021, 100, 209-216.	1.8	13
10	The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (<scp>ALWP</scp>) of the <scp>European group for blood and marrow transplantation (EBMT)</scp>. American Journal of Hematology, 2021, 96, 40-50.	4.1	10
11	Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplantation, 2021, 56, 1651-1664.	2.4	221
12	Does the order of busulfan and cyclophosphamide affect allogeneic stem cell transplantation related liver toxicity?. Annals of Hematology, 2021, 100, 1349-1350.	1.8	0
13	Immune cytopenia after allogeneic haematopoietic stem-cell transplantation: challenges, approaches, and future directions. Lancet Haematology,the, 2021, 8, e229-e239.	4.6	10
14	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. Transplantation and Cellular Therapy, 2021, 27, 267.e1-267.e5.	1.2	6
15	Blast counts are lower in the aspirate as compared to trephine biopsy in acute myeloid leukemia and myelodysplastic syndrome expressing CD56. International Journal of Laboratory Hematology, 2021, 43, 1078-1084.	1.3	1
16	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2021, 56, 2108-2117.	2.4	6
17	Lack of association of travel time to transplant center and posttransplant care model with outcome parameters after allogeneic transplantation. Bone Marrow Transplantation, 2021, 56, 2024-2026.	2.4	0
18	An ounce of which prevention is worth aâ€¦?. Blood, 2021, 137, 1852-1853.	1.4	0

#	Article	IF	Citations
19	Transfusions in Aplastic Anemia Patients Cause HLA Alloimmunization: Comparisons of Current and Past Cohorts Demonstrate Progress. Transplantation and Cellular Therapy, 2021, 27, 939.e1-939.e8.	1.2	1
20	Analysis of biological models to predict clinical outcomes based on HLA-DPB1 disparities in unrelated transplantation. Blood Advances, 2021, 5, 3377-3386.	5.2	7
21	Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. Leukemia, 2021, 35, 2875-2884.	7.2	19
22	Frequency, reactivity and evolution of human leukocyte antigen and human platelet antigen antibodies in the setting of hematopoietic cell transplantation. Transfusion and Apheresis Science, 2021, , 103301.	1.0	0
23	Transplant Outcomes in Patients with Ph+ Chronic Myeloid Leukemia: Haploidentical Donors Compared to Matched Sibling Donors and Matched/Mismatched Unrelated Donors: A Retrospective Analysis from the EBMT Chronic Malignancies Working Party (EBMT-CMWP). Blood, 2021, 138, 3959-3959.	1.4	0
24	Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT. Blood, 2021, 138, 3953-3953.	1.4	0
25	Respiratory viral infections prior to and after allogeneic haematopoietic cell transplantation. British Journal of Haematology, 2020, 188, 486-487.	2.5	1
26	Relapse of Aplastic Anemia with Majority Donor Chimerism (Donor-Type Aplasia) Occurring Late after Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 480-485.	2.0	11
27	Peripheral blood schistocytes in the acute phase after allogeneic or autologous stem cell transplantation assessed by digital microscopy. International Journal of Laboratory Hematology, 2020, 42, 145-151.	1.3	3
28	Secondary CNL after SAA reveals insights in leukemic transformation of bone marrow failure syndromes. Blood Advances, 2020, 4, 5540-5546.	5.2	3
29	New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation. In Vivo, 2020, 34, 3545-3549.	1.3	8
30	MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. Blood, 2020, 136, 2591-2595.	1.4	12
31	Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation. Annals of Hematology, 2020, 99, 2529-2538.	1.8	15
32	The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-Tâ€™s come into focus. Bone Marrow Transplantation, 2020, 55, 1604-1613.	2.4	147
33	Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation. ESMO Open, 2020, 5, e000860.	4.5	1
34	Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer: A Study of the Chronic Malignancies Working Party of the EBMT. Blood, 2020, 136, 3-4.	1.4	0
35	Baseline calprotectin fails to predict incidence of acute gastrointestinal graft vs. host disease: a prospective study. Bone Marrow Transplantation, 2019, 54, 343-347.	2.4	0
36	Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature, 2019, 572, 254-259.	27.8	246

#	Article	IF	Citations
37	Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood, 2019, 134, 892-899.	1.4	110
38	Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study. Annals of Hematology, 2019, 98, 1485-1493.	1.8	27
39	The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplantation, 2019, 54, 1575-1585.	2.4	129
40	The value of the postâ€thaw CD34+ count with and without DMSO removal in the setting of autologous stem cell transplantation. Transfusion, 2019, 59, 1052-1060.	1.6	4
41	Melphalan dose in myeloma patients â‰¥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone Marrow Transplantation, 2019, 54, 1029-1037.	2.4	18
42	The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. Haematologica, 2019, 104, 710-716.	3.5	29
43	Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 1022-1028.	2.4	19
44	Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. Journal of Clinical Investigation, 2019, 129, 1596-1611.	8.2	84
45	Outcome of Allogeneic Haematopoietic Stem Cell Transplantation in Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Study By the Chronic Malignancies Working Party of EBMT. Blood, 2019, 134, 3335-3335.	1.4	1
46	One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Blood, 2019, 134, 2035-2035.	1.4	36
47	Outcomes Following Second Allogenic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT. Blood, 2019, 134, 698-698.	1.4	1
48	The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study. Blood, 2019, 134, 412-412.	1.4	0
49	I-Care for MDS: Development of Guidelines-Based Indicators for Appropriate Care in Adult Patients with Myelodysplastic Syndromes. Blood, 2019, 134, 4752-4752.	1.4	0
50	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Therapy-Related Myeloid Neoplasm: A Study from the Chronic Malignancies Working Party of the EBMT. Blood, 2019, 134, 45-45.	1.4	1
51	Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome: A Large Series from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Blood, 2019, 134, 2053-2053.	1.4	0
52	Inert Gas Washout in Bronchiolitis Obliterans Following Hematopoietic Cell Transplantation. Chest, 2018, 154, 157-168.	0.8	18
53	Dyslipidemia and lipid-lowering treatment in a hematopoietic stem cell transplant cohort: 25Âyears of follow-up data. Journal of Clinical Lipidology, 2018, 12, 464-480.e3.	1.5	10
54	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplantation, 2018, 53, 1139-1148.	2.4	117

#	Article	IF	Citations
55	Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. Cancer Epidemiology, 2018, 52, 55-62.	1.9	8
56	Conception and Pregnancy Outcomes after Haematopoietic Stem Cell Transplant: A Retrospective Study from the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Blood, 2018, 132, 2139-2139.	1.4	3
57	Inferior Outcome of Allogeneic Stem Cell Transplantation in First Complete Remission for Secondary AML As Compared to De Novo Disease: Results from a Retrospective, Registry-Based Analysis on Behalf of the Acute Leukemia Working Party of the EBMT. Blood, 2018, 132, 2166-2166.	1.4	7
58	Post-Transplant Sorafenib Improves Overall Survival in FLT3 Mutated AML: A Report from the EBMT Acute Leukemia Working Party. Blood, 2018, 132, 708-708.	1.4	4
59	Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia. Blood, 2018, 132, 585-585.	1.4	7
60	Long-Term Follow-up of the Randomized Controlled Study in Patients with Newly Diagnosed Severe Aplastic Anemia Treated with ATG, Cyclosporine, with or without G-CSF: On Behalf of the SAA Working Party of the EBMT. Blood, 2018, 132, 1307-1307.	1.4	0
61	Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma Improved Overall Survival in Upfront Hematopoietic Stem Cell Transplantation â€" a Large Retrospective Study By the Chronic Malignancies Working Party of the EBMT. Blood, 2018, 132, 3464-3464.	1.4	0
62	Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors â€" a Retrospective Study By the EBMT Chronic Malignancies Working Party. Blood, 2018, 132, 3465-3465.	1.4	0
63	Impact of Upfront Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma with Del(17) and t(4;14): A Report from the EBMT Chronic Malignancies Working Party. Blood, 2018, 132, 2143-2143.	1.4	2
64	Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from One Antigen HLA-Mismatched Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT. Blood, 2018, 132, 1016-1016.	1.4	0
65	Red Blood Cell Allo-Antibodies after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2018, 132, 2551-2551.	1.4	1
66	Eltrombopag for the Treatment of Aplastic Anemia in Europe. Blood, 2018, 132, 1304-1304.	1.4	12
67	The Impact of Cytogenetics on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Survey from the Acute Leukemia Working Party (ALWP) of EBMT. Blood, 2018, 132, 4639-4639.	1.4	0
68	Pre-Transplant Genetic Susceptibility in Adult Allogeneic Hematopoietic Cell Transplant Recipients: Incidence and Clinical Relevance in Transplant-Associated Thrombotic Microangiopathy. Blood, 2018, 132, 3401-3401.	1.4	0
69	Prognostic Value of a New Clinically-Based Classification System in Patients with CMML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of the EBMT Chronic Malignancies Working Party. Blood, 2018, 132, 4390-4390.	1.4	0
70	Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice. Haematologica, 2017, 102, 854-864.	3.5	25
71	Human platelet antigen antibody induction in uncomplicated pregnancy is associated with HLA sensitization. Transfusion, 2017, 57, 1272-1279.	1.6	5
72	Acute myeloid leukaemia genomics. British Journal of Haematology, 2017, 179, 530-542.	2.5	82

#	Article	IF	Citations
73	Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. BioMed Research International, 2017, 2017, 1-13.	1.9	7
74	Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML. Blood, 2017, 130, LBA-5-LBA-5.	1.4	10
75	Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2016, 22, 1615-1620.	2.0	46
76	Comment: Shall Killer Cell Immunoglobulin-Like Receptor Genotyping be Incorporated in Donor Search Algorithms?. Biology of Blood and Marrow Transplantation, 2016, 22, 1539-1540.	2.0	1
77	Ibrutinib for Bridging to Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Is Safe and Effective: First Results of a Survey By the Chronic Malignancy and the Lymphoma Working Parties of the EBMT. Blood, 2016, 128, 4657-4657.	1.4	7
78	Relapse Risk Score after Allogeneic Stem Cell Transplantation for MDS Patients. an EBMT Study from the MDS Subcommittee of Chronic Malignancies Working Party (CMWP). Blood, 2016, 128, 4701-4701.	1.4	0
79	Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.. Blood, 2016, 128, 522-522.	1.4	0
80	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia (AML) with Complex Karyotypes (CK): A Retrospective Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) and MD Anderson Cancer Center (MDACC). Blood, 2016, 128, 3479-3479.	1.4	0
81	The Use of Anti-Thymocyte Globulin Is Associated with Increased Chance of Survival Free from Relapse and Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation for Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT. Blood, 2016, 128, 666-666.	1.4	0
82	Management of hemolytic anemia following allogeneic stem cell transplantation. Hematology American Society of Hematology Education Program, 2015, 2015, 378-384.	2.5	24
83	Very Long Term Stability of Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies. Bone Marrow Research, 2015, 2015, 1-6.	1.7	9
84	Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematology,the, 2015, 2, e427-e436.	4.6	88
85	Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis. Haematologica, 2015, 100, 696-702.	3.5	141
86	Allogeneic Hematopoietic Cell Transplantation for Adult Patients with ALL: Current Results and Prognostic Factors. an Analysis from Acute Leukemia Working Party of the EBMT. Blood, 2015, 126, 3202-3202.	1.4	1
87	Allogeneic Hematopoietic Transplantation in Patients with CLL: Results of a Large Disease-Specific Risk Factor Analysis. Blood, 2015, 126, 3209-3209.	1.4	1
88	Allogeneic Stem Cell Transplantation for Elderly Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia and Internal Tandem Duplication of FLT3 (FLT3-ITD); A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 4364-4364.	1.4	0
89	Very Good Response and Overall Survival after Allogeneic Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis; Results of a Non-Interventional Study By the Plasma Cell Disorder Subcommittee of the Chronic Malignancy Working Party of the EBMT. Blood, 2015, 126, 4397-4397.	1.4	0
90	Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. Haematologica, 2014, 99, 1492-1498.	3.5	19

#	Article	IF	Citations
91	Outcome of Allogeneic Stem Cell Transplantation for Patients Transformed to Myelodysplastic Syndrome or Leukemia from Severe Aplastic Anemia: A Report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1448-1450.	2.0	7
92	Post-Remission Treatment with Allogeneic Stem Cell Transplantation Improves Outcome in Patients Aged 60 Years and Older with Acute Myeloid Leukemia in First Remission. Blood, 2014, 124, 321-321.	1.4	1
93	Decreased Incidence of GvHD after Reduced Intensity Conditioning and a Fixed T-CELL Dose in Hematological Malingnancy Patients. Blood, 2014, 124, 5889-5889.	1.4	1
94	The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood. Blood, 2014, 124, 681-681.	1.4	0
95	The Comparative Value of Hematopoietic Stem Cell Transplantation and Chemotherapy in Cytogenetically Normal AML Subclassified By NPM1 Mutation Status and FLT3-ITD Allelic Ratio. Blood, 2014, 124, 323-323.	1.4	0
96	Global Hematopoietic Stem Cell Transplantation (HSCT) At One Million: An Achievement Of Pioneers and Foreseeable Challenges For The Next Decade. A Report From The Worldwide Network For Blood and Marrow Transplantation (WBMT). Blood, 2013, 122, 2133-2133.	1.4	8
97	Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries. Swiss Medical Weekly, 2013, 143, w13757.	1.6	4
98	Comparison Of Intensive Chemotherapy and Hypomethylating Agents Prior To Allogeneic Stem Cell Transplantation For Advanced MDS (RAEB, RAEB-T). A Study Of The MDS Subcommittee Of The Cmwp Of EBMT. Blood, 2013, 122, 2121-2121.	1.4	0
99	Prognostic Value Of Five-Group Cytogenetic Risk Classification In Patients With MDS After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study Of The Chronic Malignancies Working Party Of The EBMT. Blood, 2013, 122, 2092-2092.	1.4	0
100	Global Trends in Hematopoietic Cell Transplantation.. Blood, 2012, 120, 3143-3143.	1.4	2
101	Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with T-Cell Acute Lymphoblastic Leukemia: A Survey From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2012, 120, 356-356.	1.4	4
102	Hematopoietic stem cell transplantation: a review and recommendations for follow-up care for the general practitioner. Swiss Medical Weekly, 2012, 142, w13696.	1.6	32
103	Outcome of Aplastic Anemia in Children. A Survey On Behalf of the SAA and PDWP of the EBMT. Blood, 2012, 120, 643-643.	1.4	0
104	Donor Characteristics Affecting Graft Failure, Graft-versus-Host Disease, and Survival after Unrelated Donor Transplantation with Reduced-Intensity Conditioning for HematologicÂMalignancies. Biology of Blood and Marrow Transplantation, 2011, 17, 1869-1873.	2.0	31
105	Global Use and Trends in Hematopoietic Stem Cell Transplantation Analyzed by the Worldwide Network of Blood and Marrow Transplantation WBMT: A Targeted Approach for a Widening Gap. Blood, 2011, 118, 1016-1016.	1.4	1
106	Prognostic Impact of Iron Overload During Follow-up After Allogeneic Stem Cell Transplantation. Blood, 2011, 118, 347-347.	1.4	0
107	Prospective Phase II Pilot Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline) with Ciclosporin for Patients with Acquired Aplastic Anemia and Matched Pair Analysis with Patients Treated with Horse ATG (Lymphoglobuline) and Ciclosporin: A Study From the EBMT Severe Aplastic Anemia Working Party (RATGAA07). Blood, 2011, 118, 2408-2408.	1.4	1
108	Allogeneic Transplantation for Multiple Myeloma â€“ the Swiss Experience. Blood, 2011, 118, 3112-3112.	1.4	0

#	Article	IF	Citations
109	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40â€“60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning. Blood, 2011, 118, 159-159.	1.4	1
110	Cyclophosphamide-Busulfan Instead of Busulfan-Cyclophosphamide for Conditioning in Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 2268-2268.	1.4	0
111	Preemptive Immunotherapy with Highly Purified CD56+/CD3â^' Natural Killer Cells after Haploidentical Stem Cell Transplantation. A Prospective Phase II Study in 2 Centers.. Blood, 2006, 108, 411-411.	1.4	0
112	High Dose Chemotherapy Using Beam without Autologous Rescue Followed by Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Refractory or Relapsing Lymphomas - A Comparison of Delayed Versus Immediate Transplantation.. Blood, 2006, 108, 5352-5352.	1.4	0
113	A Gain-of-Function Mutation ofJAK2in Myeloproliferative Disorders. New England Journal of Medicine, 2005, 352, 1779-1790.	27.0	3,240
114	Sideroblastic Changes Can Be Recognized in the Erythrogram.. Blood, 2005, 106, 4909-4909.	1.4	0
115	Birth Order and Outcome in HLA-Identical Sibling Donor Hematopoietic Stem Cell Transplants. Impact of a Sequential Fetomaternal - Maternofetal Cell Transfer?.. Blood, 2005, 106, 2034-2034.	1.4	0
116	Impact of Molecular HLA Matching for Allogeneic Stem Cell Transplantation from Unrelated Donors.. Blood, 2004, 104, 979-979.	1.4	1
117	Donor Hematopoietic Stem Cells Did No Major Contribution to Hair Follicle Repair Either in Short or in Long Term Allogeneic Hematopoietic Stem Cell Transplants Recipients.. Blood, 2004, 104, 4167-4167.	1.4	0